Developing the future of cancer treatment

Fighting cancer by local killing of tumor cells and activation of the immune system

Q3 2024 results presentation

19.11.2024

Lytix Biopharma

Disclaimer

This presentation (the "Presentation") has been prepared by Lytix Biopharma AS ("Company") exclusively for information purposes.

The Presentation is being made only to, and is only directed at, persons to whom such presentation may lawfully be communicated (’relevant persons’). Any person who is not a relevant person should not act or rely on the Presentation or any of its contents.

The Presentation does not constitute an offering of securities or otherwise constitute an invitation or inducement to any person to underwrite, subscribe for or otherwise acquire securities in the Company. The release, publication or distribution of the Presentation in certain jurisdictions may be restricted by law, and therefore persons in such jurisdictions into which this Presentation is released, published or distributed should inform themselves about, and observe, such restrictions.

The Presentation contains certain forward-looking statements relating to the business, products, financial performance and results of the Company and/or the industry in which it operates. Forward-looking statements concern future circumstances and results and other statements that are not historical facts, sometimes identified by the words “believes”, expects”, "predicts", "intends", "projects", "plans", "estimates", "aims", "foresees", "anticipates", "targets", and similar expressions. The forward-looking statements contained in the Presentation, including assumptions, opinions and views of the Company or cited from third party sources are solely opinions and forecasts which are subject to risks, uncertainties and other factors that may cause actual events to differ materially from any anticipated development. Neither the Company nor its employees provides any assurance that the assumptions underlying such forward-looking statements are free from errors nor does any of them accept any responsibility for the future accuracy of the opinions expressed in the Presentation or the actual occurrence of the forecasted developments. The Company assumes no obligation, except as required by law, to update any forward-looking statements or to conform these forward-looking statements to its actual results.

The Presentation contains information obtained from third parties. You are advised that such third-party information has not been prepared specifically for inclusion in the Presentation and the Company has not undertaken any independent investigation to confirm the accuracy or completeness of such information.

An investment in the Company involves risk, and several factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by statements and information in the Presentation, including, among others, the risk factors described in the Company's information document dated 14 June 2021. Should any risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in the Presentation.

No representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and, accordingly, neither the Company nor its directors or employees accepts any liability whatsoever arising directly or indirectly from the use of the Presentation.

By attending or receiving the Presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company’s business.

The Presentation speaks as of November 19, 2024. Neither the delivery of this Presentation nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since such date.

Presenting team

Øystein Rekdal, CEO

Co-founder of Lytix Biopharma, Dr. Rekdal has served as CEO twice, most recently since 2019. With a PhD in tumor immunology, his expertise in anticancer molecules from host defense peptides underpins Lytix's technology. He is a regular speaker at international oncology conferences and was instrumental for the licensing deal with Verrica Pharmaceuticals.

Gjest Breistein, CFO

Mr. Breistein, a state-authorized public accountant, joined Lytix in 2017 after advising companies at PwC on capital market transactions. He holds Master’s degrees in Applied Economics and Finance (Copenhagen Business School) and Professional Accountancy (BI Norwegian School of Management).



Lytix Biopharma

Company introduction

Lytix Biopharma

Developing the future of cancer treatment

Lytix Biopharma

Clinical-stage, immune-oncology company developing a new class of cancer therapy

Fighting cancer through local killing of tumor cells and activation of the immune system

Positive phase II results in basal cell carcinoma and melanoma

Licensing deal with Nasdaq-listed Verrica Pharmaceuticals Inc.

Nobel Prize winner in immune oncology member of Lytix's Advisory Board

Lytix is addressing the two major shortcomings in current cancer immunotherapy

CHALLENGE

Cancer cells vary from one another in solid tumors (tumor heterogeneity) leading to therapy resistance

SOLUTION

Lytix technology able to kill all cancer cell variants in treated tumors and activate a broad immune response

CHALLENGE

Majority of cancer patients have "**cold**" tumors and therefore do not respond to current immunotherapy

SOLUTION

Lytix technology converts «**cold**» tumors to «**hot**» tumors that respond better to immune therapy



Lytix Biopharma

Lytix's solution works through two phases; killing tumors locally and activating a systemic broad immune response



Lytix Biopharma

Clinical progress



Q3 Highlights

Lytix Biopharma

Highlights for the third quarter (I/II)

- And post quarter end

Very promising top-line Results achieved in Phase II study in basal cell carcinoma (BCC)

- An 86% overall reduction in tumor size was observed, with complete clearance achieved in 51% of patients.
- LTX-315 demonstrates the potential as a first-line treatment option for BCC.
- The positive top-line results were presented at the 2024 Fall Clinical Dermatology Conference (October 24-27th).

ATLAS-IT-05 – Encouraging new interim data from 20 late-stage and heavily pre-treated melanoma patients

- 40% of patients experienced disease control, with stabilization lasting up to 20 months.
- Sustained partial response obtained in two patients.

The first patient has been treated in the new phase II NeoLIPA study

- This study examines the impact of Lytix's lead drug candidate, LTX-315, in early-stage melanoma patients.
- Melanoma, the most severe type of skin cancer with increasing global incidence, is projected to reach a global market size of USD 11 billion by 2030[1].

Lytix Biopharma

1) https://www.grandviewresearch.com/industry-analysis/melanoma-therapeutics-market

Highlights for the third quarter (II/II)

- And post quarter end

The new superior formulation of LTX-401 may represent a significant advancement for Lytix's second lead candidate.

- This new formulation of LTX-401 has demonstrated substantially improved anticancer effects, with the added benefit of extending patent life.
- Lytix is preparing to seek scientific advice from European regulatory authorities to strategically advance this formulation into clinical development.

Financials

- Cash at the end of the period amounted to NOK 43.5 million. The cash runway is expected to take Lytix into 2025.

Clinical/Operational update

Lytix Biopharma

Clinical/Operational update

1. Phase II study: Basal cell carcinoma (Verrica Pharmaceuticals)
2. Phase II study: Late stage melanoma (ATLAS-IT-05)
3. New phase II study: Early stage melanoma (NeoLIPA)
4. LTX-401

Lytix Biopharma

Study:
Verrica Ph. II
Completed

Lytix's lead drug candidate shows great potential in the largest cancer disease globally

- Basal Cell Carcinoma (BCC) represent a large and growing market **expected to grow to USD 11.5bn in 2028**
- BCCs are typically found in skin more exposed to the sun, **95%** of the patients are treated with **surgery**
- Diagnosed BCC patients have a **35% chance of new lesion** within 3 years, and **50% within 5 years**[1,2]
- **Phase II indicates the potential to be utilized as a first-line therapy, an instrumental milestone towards commercialization**
- A licensing deal in place with US-based Verrica Pharmaceuticals with global rights for skin cancer (except mMelanoma and mMerkel cell carcinoma), **potentially up to USD 110m + royalties on future sale**

Lytix Biopharma

1. Chung, Seum. "Basal cell carcinoma." *Archives of Plastic Surgery* 39.02 (2012): 166-170.
2. Lewis KG, Weinstock MA. Trends in nonmelanoma skin cancer mortality rates in the United States, 1969 through 2000. J Invest Dermatol 2007;127:2323-7.

Study:
Verrica Ph. II
Completed

LTX-315: First line treatment potential, less invasive for patients

- BCCs are typically found in skin more exposed to the sun, with ~80% located on the face and head
- ~95 % of BCC patients are treated with surgery.
- Surgery often cause scarring that are larger than the visible BCC lesion
- LTX-315 Treatment:
  - **Complete histological clearance (51%)**
    - No need for surgery
  - **Partial clearance (49%)**
    - Significant reduction in size of lesion that did not achieve complete clearance (71%)
    - Significant reduction in size of target surgical area and any potential surgical scar
- Immune and genomic data is being generated to confirm previous evidence from Lytix studies of LTX-315's ability to induce cancer-specific immune responses

Current treatment options are invasive

Before



After

After



Source: https://www.tv2.no/nyheter/viral/kenneth-40-trodde-han-hadde-kvise-pa-nesen-fikk-alvorlig-beskjed-hos-legen/14511455

1: https://tidsskriftet.no/2021/06/debattartikler/basalcellekarsinomer-i-ansiktet-feilbehandles-ofte

Study:
Verrica Ph. II
Completed

Commercially validated through partnering with Verrica Pharmaceuticals

RECENT DEVELOPMENTS

- **The partnership**
  - LTX-315 (VP-315) remains a core asset for both Verrica and Lytix with positive phase II results in BCC and melanoma, respectively for each company.
  - Lytix remans fully committed to support Verrica in driving efficient development and any future commercialization efforts for LTX-315 for basal cell carcinoma (BCC)
- **Verrica has implemented several actions to improve profitability:**
  - **New leadership:**
    - Jayson Rieger, PhD, MBA, new CEO of Verrica.
    - He brings 20 years of experience across business development, operations, drug discovery, and product development in life sciences.
    - Dr. Rieger has served as a member of Lytix's Board of Directors since 2021 and is well-positioned with knowledge about LTX-315 to help drive the advancement of LTX-315 in basal cell carcinoma.
  - **Financial Support:** Jefferies, a leading global investment bank, have been engaged by Verrica to explore funding solutions.

The partnership

→ Verrica Pharmaceuticals has a worldwide license to develop and commercialize LTX-315 for dermatological oncology indications* from 2020.

→ Phase II trial in basal cell carcinoma with LTX-315 (named VP-315 in Verrica's study)

→ Under the license agreement, Lytix may receive aggregate payments of up to USD 110 million upon achieving certain clinical, regulatory, in addition to sales milestones and tiered royalty payments in the double-digit teens.

Lytix Biopharma

VERRICA PHARMACEUTICALS
Reinventing Skin Science

*Except for metastatic melanoma and metastatic Merkel cell carcinoma

Clinical/Operational update

1. Phase II study: Basal cell carcinoma (Verrica Pharmaceuticals)
2. Phase II study: Late stage melanoma (ATLAS-IT-05)
3. New phase II study: Early stage melanoma (NeoLIPA)
4. LTX-401

Lytix Biopharma

ATLAS-IT-05 (ongoing): Promising effects of LTX-315 in heavily pre-treated patients with late-stage melanoma

Study:
ATLAS-IT-05
Ongoing

- LTX-315 and PD-1 inhibitor pembrolizumab are being tested in late-stage melanoma patients that have previously failed to respond to PD-(L)1 inhibitor therapy

- Enrolled patients had failed ≤3 prior lines of treatment, e.g. double checkpoint inhibition or BRAF/MEK inhibition or oncolytic virus

!

Positive interim data from 20 evaluable patients

- Disease control in 40% of the patients with stabilization of the disease up to 20 months
- Two patients achieving a durable partial response
- Impressive effects in both injected and non-injected lesions
- Three patients still receiving study treatment (pembrolizumab)

Complete regression in injected tumors



Before Treatment



Day 43

Lytix Biopharma

Impressive tumor shrinkage in patient with partial response

- Prior treatment with nivolumab (PD-1 inhibitor) and BRAF/MEK inhibitors
- **Complete response** in all 4 LTX-315 injected lesions
- **Complete response** in a non-injected lesion
- Duration of response of >1,5 years and patient still on study treatment (pembrolizumab)

Study:
ATLAS-IT-05
Ongoing

Complete regression in non-injected tumors

Baseline scan – **28 mm** lesion in left gluteus muscle



Day 547 scan – **no** lesion in left gluteus muscle



Lytix Biopharma

Clinical/Operational update

1. Phase II study: Basal cell carcinoma (Verrica Pharmaceuticals)
2. Phase II study: Late stage melanoma (ATLAS-IT-05)
3. New phase II study: Early stage melanoma (NeoLIPA)
4. LTX-401

Lytix Biopharma

NeoLIPA – Moving to early-stage melanoma

Oslo University Hospital

Study: NeoLIPA Started

Study Overview

- Evaluate LTX-315 in combination with pembrolizumab (PD-1 inhibitor), administered prior to surgery, to reduce relapse risk in patients with resectable melanoma
- Investigator driven study led by Dr. Henrik Jespersen, Head of Melanoma at Oslo University Hospital, ensuring low costs for Lytix
- First patient treated with LTX-315 in November ‘24

Study design and Expectations

- Early-stage melanoma patients with a stronger immune system
- Quick read-out with effect on treated tumor before surgery as the primary endpoint; secondary endpoints include time to relapse and overall survival
- Enrollment of approximately 27 patients, with interim results expected in H2 2025 and final top-line results anticipated in H1 2026

Commercial Rationale

- Early-stage melanoma patients have less advanced disease and a more robust immune system, increasing the likelihood of response to Lytix’s immunotherapy
- This patient population is larger, translating into significant commercial potential

Lytix Biopharma

Clinical/Operational update

1. Phase II study: Basal cell carcinoma (Verrica Pharmaceuticals)
2. Phase II study: Late stage melanoma (ATLAS-IT-05)
3. New phase II study: Early stage melanoma (NeoLIPA)
4. LTX-401

Lytix Biopharma

LTX-401 – a small oncolytic molecule with a large commercial potential in deep seated cancer

Small oncolytic molecule in development

- Increased commercial interest with a clinical validation of our lead candidate LTX-315
- Meeting with regulatory authorities in Europe, to seek advice on how to bring this novel and potentially transformative LTX-401 formulation to patient planned Q4 2024

Small molecule

Similar mode-of-action as LTX-315 with superior effects in liver cancer models

Significant commercial potential

Suited for treatment of various solid tumor types, including deep-seated lesions

New superior formulation

Improved anti-cancer effects and potential to extend patent life for LTX-401

Synergy effects

Demonstrates strong synergy with checkpoint inhibitors



LTX-401

Lytix Biopharma

Financials and outlook

Key figures – profit and loss

Amounts in NOK '000	Q3 2024	Q3 2023	FY 2023
Total operating income	231	3,917	3,991
Total operating expenses	(23,280)	(22,537)	(100,776)
Loss from operations	(23,049)	(18,620)	(96,785)
Loss for the period	(22,738)	(18,237)	(87,897)

- Operating income for the period primarily arises from stability testing of LTX-315 performed on behalf of Verrica
- The rise in total operating expenses is mainly due to increased direct R&D costs. The ATLAS-IT-05 study maintains high activity as patient treatments continue across multiple hospitals. Additionally, preparations for a Phase I trial of the newly formulated LTX-401 are underway

Financial costs and cash position

Stable cost development despite significant R&D activities

Total operating expenses



Cash and short-term financial investments



*) NOK 9.2 million in cost for production of LTX-315 sold to Verrica in Q1 2024 has been excluded

- Direct R&D expenses rose by NOK 3.4 million compared to Q3 2023. The ATLAS-IT-05 trial is currently at a stage where a few patients remain in the study, while we are concurrently closing down sites and activities that are no longer essential. This approach aims to efficiently conclude the study.
- Payroll and related expenses decreased by NOK 1.3 million compared to Q3 2023 while other expenses decreased by NOK 1.3 million and is a result of the cost-saving initiative aimed at enhancing its operations and organizational efficiency to prioritize the Company's clinical development efforts.

Key figures – balance sheet

Amounts in NOK '000	30.09.2024	30.09.2023	31.12.2023
Assets			
Property, plant and equipment	59	127	110
Right-of-use assets	2,793	663	438
Trade and other receivables	9,902	1,252	12,777
Short-term financial investments	-	32,609	23,183
Cash and cash equivalents	43,529	46,158	27,365
Total assets	**56,283**	**80,810**	**63,874**
Shareholder's equity and liabilities			
Total equity	36,830	68,884	51,319
Total liabilities	19,453	11,925	12,555
Total equity and liabilities	**56,283**	**80,810**	**63,874**

- At the end of the period, cash plus short-term financial investments were NOK 43.5 million, compared to NOK 50.5 million as of 31 December 2023 and NOK 78.8 million as of September 30, 2023.
- In last quarter, Lytix raised NOK 50 million in a share offering primarily directed towards existing shareholders. The cash runway is expected to take Lytix into Q2 2025.

Executing on our strategy – upcoming events

- **Verrica - BCC**
  - Clinical Study Report (**Q4 2024**)
  - Analysis of Immune responses **(Q1 2025)**
  - FDA- End of Phase 2 meeting (**H1 2025)**

- **Lytix Clinical Development**
  - Interim results from NeoLIPA (**2025)**
  - LTX-401 meeting with regulatory authorities **(Q4 2024)**
  - Finalization of ATLAS-IT-05 study **(H2 2025)**

- **Lytix Business Development**
  - Continue to aim for late-stage development and commercialization through partnerships

Lytix Biopharma

Lytix Biopharma's roadmap to create shareholder value

Non-metastatic skin cancer

LTX-315: Clear path towards commercialization, demonstrated through licensing with Verrica Pharmaceuticals

Milestone payments and royalties secured for future revenue streams

Metastatic skin cancer

LTX-315: Phase II results in NeoLIPA
Interim data H2 2025
Final results H1 2026

Start dialog with mid-size/big pharma H2-2025 - 2026

Deep seated cancer

LTX-401: Phase I study in deep seated tumors (2026)
Technology partly validated by LTX-315

Start dialog with mis-size/big pharma H2 2025 - 2026

Q&A

Lytix Biopharma

Interim financial statements

Condensed interim statement of profit and loss

Amounts in NOK thousands	*Unaudited* Q3 2024	*Unaudited* Q3 2023	*Unaudited* YTD 2024	*Unaudited* YTD 2023	FY 2023
Revenue	231	3,917	10,757	3,991	3,991
Other operating income	-	-	-	-	-
Total operating income	**231**	**3,917**	**10,757**	**3,991**	**3,991**
Payroll and related expenses	(4,859)	(6,192)	(15,237)	(18,749)	(24,344)
Depreciation and amortization expenses	(221)	(242)	(693)	(720)	(962)
Direct R&D expenses	(16,315)	(12,952)	(49,671)	(52,524)	(63,167)
Other expenses	(1,884)	(3,151)	(8,429)	(9,201)	(12,303)
Total operating expenses	**(23,280)**	**(22,537)**	**(74,031)**	**(81,195)**	**(100,776)**
Loss from operations	**(23,049)**	**(18,620)**	**(63,274)**	**(77,203)**	**(96,785)**
Net financial items	**311**	**383**	**919**	**7,872**	**8,887**
Loss before tax	**(22,738)**	**(18,237)**	**(62,355)**	**(69,331)**	**(87,897)**
Tax expense	**-**	**-**	**-**	**-**	**-**
Loss for the period	**(22,738)**	**(18,237)**	**(62,355)**	**(69,331)**	**(87,897)**

Condensed interim statement of financial position

Amounts in NOK thousands	*Unaudited* 30.09.2024	*Unaudited* 30.09.2023	31.12.2023
Assets			
Non-current assets			
Property, plant and equipment	59	127	110
Right-of-use assets	2,793	663	438
Total non-current assets	**2,853**	**790**	**548**
Current assets			
Trade and other receivables	9,902	1,252	12,777
Short-term financial investments	-	32,609	23,183
Cash and cash equivalents	43,529	46,158	27,365
Total current assets	**53,431**	**80,019**	**63,326**
Total assets	**56,283**	**80,810**	**63,874**
Shareholder's equity and liabilities			
Issued capital and reserves			
Share capital	4,961	4,007	4,007
Share premium reserve	31,869	64,878	47,312
Total equity	**36,830**	**68,884**	**51,319**
Liabilities			
Non-current liabilities			
Lease liabilities	2,074	41	41
Total current liabilities	**2,074**	**41**	**41**
Current liabilities			
Trade payables	2,443	22	3,572
Other current liabilities	14,190	11,173	8,492
Lease liabilities	746	690	451
Total current liabilities	**17,379**	**11,885**	**12,514**
Total liabilities	**19,453**	**11,925**	**12,555**
Total equity and liabilities	**56,283**	**80,810**	**63,874**

Lytix Biopharma

Condensed interim statement of cash flows

Amounts in NOK thousands	*Unaudited* Q3 2024	*Unaudited* Q3 2023	*Unaudited* YTD 2024	*Unaudited* YTD 2023	FY 2023
Cash flows from operating activities					
Loss for the period	**(22,738)**	(18,236)	**(62,355)**	(69,331)	(87,897)
Adjustments for:					
Depreciation of property, plant and equipment	**17**	17	**51**	45	62
Depreciation of right-of-use assets	**204**	225	**643**	675	900
Interest income/(expense), net	**(70)**	(573)	**(434)**	(1,915)	(2,348)
Share-based payment expense	**347**	1,078	**877**	3,182	4,183
Increased/decreased in trade and other receivables	**4,508**	4,707	**2,875**	5,483	(6,042)
Increased/decreased in trade and other payables	**1,187**	(9,004)	**4,569**	(5,696)	(4,828)
Cash generated from operations	**(16,545)**	**(21,787)**	**(53,774)**	**(67,557)**	**(95,969)**
Income tax paid	**-**	-	**-**	-	-
Net cash flows from operations	**(16,545)**	**(21,787)**	**(53,774)**	**(67,557)**	**(95,969)**
Investing activities					
Investments in tangible assets	**-**	-	**-**	(49)	(49)
Interest received	**72**	573	**435**	1,917	2,315
Increase/decrease in other investments	**-**	9,353	**23,183**	17,998	27,423
Net cash from/(used in) investing activities	**72**	**9,926**	**23,619**	**19,866**	**(29,725)**
Financing activities					
Interest paid	**(2)**	-	**(2)**	(2)	(3)
Proceeds from share issue	**-**	-	**50,000**	-	-
Transaction cost	**-**	-	**(3,011)**	-	-
Payment of principal portion of lease liabilities	**(177)**	(236)	**(668)**	(700)	(940)
Net cash from/(used in) financing activities	**(179)**	**(236)**	**46,319**	**(702)**	**(943)**
Net increase/(decrease) in cash and cash equivalents	**(16,652)**	(12,098)	**16,164**	(48,393)	(67,187)
Cash and cash equivalents at the beginning of the period	**60,181**	58,257	**27,365**	94,552	94,552
Cash and cash equivalents at the end of the period	**(43,529)**	**46,158**	**43,529**	**46,158**	**27,365**

Lytix Biopharma